Ernesto Relova-Hernandez
Overview
Explore the profile of Ernesto Relova-Hernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Decoupling immunomodulatory properties from lipid binding in the α-pore-forming toxin Sticholysin II
Rivero-Hernandez A, Hervis Y, Valdes-Tresanco M, Escalona-Rodriguez F, Cancelliere R, Relova-Hernandez E, et al.
Int J Biol Macromol
. 2024 Oct;
280(Pt 4):136244.
PMID: 39368578
Sticholysin II (StII), a pore-forming toxin from the marine anemone Stichodactyla helianthus, enhances an antigen-specific cytotoxic T lymphocyte (CTL) response when co-encapsulated in liposomes with a model antigen. This capacity...
2.
Perez-Masson B, Quintana-Perez Y, Tundidor Y, Perez-Martinez D, Castro-Martinez C, Pupo-Merino M, et al.
Sci Rep
. 2024 Jan;
14(1):712.
PMID: 38184672
SARS-CoV-2 receptor binding domain (RBD) mediates viral entry into human cells through its interaction with angiotensin converting enzyme 2 (ACE2). Most neutralizing antibodies elicited by infection or vaccination target this...
3.
Boggiano-Ayo T, Palacios-Oliva J, Lozada-Chang S, Relova-Hernandez E, Gomez-Perez J, Oliva G, et al.
Front Bioeng Biotechnol
. 2023 Dec;
11:1287551.
PMID: 38050488
We have developed a single process for producing two key COVID-19 vaccine antigens: SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are featured in various COVID-19 vaccine formats,...
4.
Rojas G, Relova-Hernandez E, Perez-Riveron A, Castro-Martinez C, Diaz-Bravo O, Cabrera Infante Y, et al.
Commun Biol
. 2023 Aug;
6(1):828.
PMID: 37558752
Interleukin-2 (IL-2) engineered versions, with biased immunological functions, have emerged from yeast display and rational design. Here we reshaped the human IL-2 interface with the IL-2 receptor beta chain through...
5.
Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernandez S, Rodriguez L, Sanchez Ramirez B, et al.
ACS Chem Biol
. 2021 Jul;
16(7):1223-1233.
PMID: 34219448
Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies...
6.
Dorvignit D, Boligan K, Relova-Hernandez E, Clavell M, Lopez A, Labrada M, et al.
Sci Rep
. 2019 Jul;
9(1):9921.
PMID: 31289278
The GM3(Neu5Gc) ganglioside represents a tumor-specific antigen that is considered a promising target for cancer immunotherapy. We previously demonstrated that the humanized antibody 14F7hT, specific for this ganglioside, exhibited significant...